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Volumetric muscle loss (VML) is associated with loss of skeletal muscle function, and current
treatments show limited efﬁcacy. Here we show that bioconstructs suffused with genetically-
labelled muscle stem cells (MuSCs) and other muscle resident cells (MRCs) are effective to
treat VML injuries in mice. Imaging of bioconstructs implanted in damaged muscles indicates
MuSCs survival and growth, and ex vivo analyses show force restoration of treated muscles.
Histological analysis highlights myoﬁbre formation, neovascularisation, but insufﬁcient
innervation. Both innervation and in vivo force production are enhanced when implantation of
bioconstructs is followed by an exercise regimen. Signiﬁcant improvements are also observed
when bioconstructs are used to treat chronic VML injury models. Finally, we demonstrate that
bioconstructs made with human MuSCs and MRCs can generate functional muscle tissue in
our VML model. These data suggest that stem cell-based therapies aimed to engineer tissue
in vivo may be effective to treat acute and chronic VML.
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V
olumetric muscle loss (VML) is deﬁned as an irrecover-
able injury sustained by skeletal muscle and characterized
by a permanent loss of tissue structure and function1. The
result is life-long disability attributed to scar tissue formation and
structural changes2,3. Currently, state-of-the-art treatments are
limited to scar tissue debridement and placement of muscle ﬂaps
around the site of tissue defects4,5. Unfortunately, these two
clinical options are inefﬁcient and the outcomes remain
aesthetically and functionally deﬁcient2,6.
At the root of muscle injury repair and regeneration, exists
a population of resident adult muscle stem cells (MuSCs),
or ‘satellite cells’, that, in uninjured muscle, reside embedded
under the basal laminae of muscle ﬁbres in a quiescent state7,8.
In response to even minor injuries, MuSCs activate and give
rise to myogenic progenitor cells that can fully restore the original
structure and function of the tissue3,9. Moreover, during regene-
rative processes of the muscle tissue, MuSCs are supported by
other cell types10,11. However, despite their remarkable
regenerative potential, MuSCs fail to restore tissue structure
and function when faced with the extensive damage associated
with VML lesions10,12. Importantly, recent ﬁndings showed that
acellular muscle architecture is indeed required to properly guide
MuSCs during muscle regeneration13.
It has been suggested that transplantation of scaffolds composed
of extracellular matrix (ECM) proteins promote the repair of VML
injury by providing a structural and biochemical framework14,15.
Recent reports indicate that culturing myogenic cells in
decellularized ECM-based scaffolds prior to transplantation results
in some functional and structural repair of VML lesions16–18. Other
studies using hydrogels to support transplanted cells have
demonstrated that MuSCs can partially restore the structure and
function of injured muscle17,19,20. Nevertheless, a tissue engineering
system capable of restoring even near normal mature muscle,
vasculature and ECM composition to the damaged tissue has yet to
be achieved. More importantly, achieving de novo innervation of
regenerated myoﬁbres remains a critical step for functional
restoration of VML injuries.
Here, we engineer a novel VML treatment based on a strategy
designed to mimic the endogenous niche of MuSCs within
transplantable bioconstructs. We ﬁnd that bioconstructs
generated with MuSCs and muscle resident cells (MRCs) are
capable of restoring structure and function of muscles with acute
and chronic VML injuries. A regimen of exercise further
improves innervation and force production in vivo. Finally,
bioconstructs generated with human MuSCs and MRCs result in
functional muscle tissue in our VML model. These advances in
stem cell-based methods may offer new tools to design treatments
for VML in the clinical setting.
Results
Characterization of the VML model. With the goal of developing
treatment strategies capable of ameliorating the regenerative deﬁcits
of VML injuries, we ﬁrst sought to generate a dependable,
reproducible and anatomically accessible murine VML model.
Based on previous models21–23, we developed a VML model using
the tibialis anterior (TA) muscle of mice. We used a 40% surgical
ablation of the TA muscle and we assessed the injured muscles over
the next 30 days (Fig. 1a,b). As expected, we observed that the
ablated TA muscle was unable to regenerate to any meaningful
extent (Fig. 1c). To further characterize this lasting deﬁcit, we
weighed the ablated muscles and found a permanent loss of muscle
mass compared with uninjured muscles (Fig. 1d). By adding the
mass of each ablated mass with the mass of the remaining
tissue 30 days after injury and comparing it with that of the
uninjured contralateral TA muscle, we conﬁrmed that no
signiﬁcant compensatory hypertrophy or partial recovery had
occurred (Fig. 1d). In vivo muscle force production of the TA
muscles was quantiﬁed by stimulating the sciatic nerve and directly
measuring biomechanics in situ by attaching the transducer to
the TA distal tendon. The ablated TA muscles showed B40%
reduction in force when compared with uninjured muscles
(Fig. 1e). Similarly, direct ex vivo electrical stimulation of the
dissected muscles resulted in force reduction of B50% compared
with uninjured muscles (Fig. 1e). These results suggest that our
deﬁned surgical ablation resulted in consistent and permanent loss
of TA mass and function, characteristic of VML injuries.
Scaffolds with MuSCs result in de novo myoﬁbres in vivo.
Previous studies in which MuSCs were directly introduced
into damaged muscle have resulted in limited de novo muscle
formation9,24. Many investigators have achieved better stem or
progenitor cell engraftment by ﬁrst implanting the cells onto
3D scaffolds prior to transplantation19,20,25. Thus, we sought to
test whether MuSCs, transplanted in combination with a 3D
scaffold composed of decellularized muscle tissue, might display
enhanced regenerative capacity compared with decellularized
muscle alone or MuSCs alone.
To assess the ability of MuSCs to generate new muscle ﬁbres in
our VML model, we isolated MuSCs from the hind limb muscles
of mice using ﬂuorescent activated cell sorting (FACS). We
injected these MuSCs into decellularized TA muscle scaffolds
in preparation for transplantation (Supplementary Fig. 1a).
However, direct injection of MuSCs in suspension into the
decellularized scaffold proved to be an ineffective means to
prepare cells for transplantation because of poor cellular retention
within the scaffold. We thus tested whether suspending cells in
more viscous solutions prior to injection into the scaffolds would
enhance the retention of cells.
Hydrogels have been used extensively as biocompatible
substrates for maintaining viable 3D MuSC cultures in both
in vitro and in vivo applications19,26. We screened different
hydrogel formulations for their capacity to sustain MuSC viability.
We isolated MuSCs from mice expressing the bioluminescent
reporter proteins Luciferase and GFP (FVB-Tg(CAG-luc,-GFP)-
L2G85Chco/J) and cultured them in various experimental hydrogel
formulations (see Supplementary Table 1). After 48h in culture, we
administered luciferin and measured bioluminescence using an
imaging system (IVIS) (Supplementary Fig. 1b). Cells cultured in a
Collagen I hydrogel or in an ECM hydrogel emitted the highest
bioluminescent signals, suggesting that they were the most effective
in maintaining cell viability.
Upon demonstrating the highest propensity of MuSCs to
survive in these two hydrogels in vitro, we next assessed their
contribution to our cellular reconstitution and transplantation
strategy. First, we suffused MuSCs in solutions of ECM or
Collagen I and microinjected them into the scaffolds. Completed
bioconstructs were deemed ready for transplantation once the
gels had formed and cured (typically 30–60min). We then
transplanted bioconstructs generated into our VML model and
analysed the muscles histologically after 10 days. Within the
bioconstructs, the myoﬁbres stained positive for embryonic
Myosin Heavy Chain (eMHC) (Supplementary Fig. 1c), providing
evidence of de novo myoﬁbre formation. Bioconstructs generated
using MuSCs suspended in ECM-based hydrogel (compared with
Collagen I hydrogel or no hydrogel) resulted in the highest
number of myoﬁbres per region of interest (Supplementary
Fig. 1d).
Muscle tissue formation by MuSCs is supported by a number
of other MRCs25,27,28. These MRCs include ﬁbro-adipogenic
progenitors (FAPs), macrophages and endothelial cells11,29–32.
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We used FACS to isolate four distinct populations of
mononucleated cells based on cell surface markers33,34:
(1) MuSCs (VCAMþ /CD45 /CD31 /Sca1 ); (2) hemato-
poietic cells, or HCs (VCAM /CD45þ /CD31 /Sca1 );
(3) endothelial cells, or ECs (VCAM /CD45 /CD31þ /
Sca1þ ); (4) FAPs (VCAM /CD45 /CD31 /Sca1þ ); and
(5) a population which was negative for all cell surface proteins
(VCAM /CD45 /CD31 /Sca1 ) (Fig. 2a). In vitro
characterization of this marker-negative population revealed it
to be enriched in ﬁbroblast-like cells (FLCs) (Supplementary
Fig. 2a,b).
We assessed how supplementing our bioconstructs with these
various cell types (which, together, we refer to as MRCs) might
enhance the efﬁcacy of MuSCs in mediating de novo myoﬁbre
formation following transplantation into VML lesions. We
generated MuSCþ /MRC and MuSCþ /MRCþ bioconstructs
containing Luciferase-expressing (Lucþ ) MuSCs with MRCs
isolated from Luc mice. We reconstituted scaffolds with
ECM-based hydrogels suffused either with 150,000 MuSCs alone
(MuSCþ /MRC ) or with 150,000 MuSCs plus 350,000 MRCs
(MuSCþ /MRCþ ). For the MuSCþ /MRCþ formulations, the
relative numbers of cells from each population were based upon
the cell ratios recorded during the initial FACS analysis (Fig. 2a
and Methods). We cultured them for up to 3 days, comparing
MuSC survival by measuring bioluminescence over time. Much
higher bioluminescence signals, indicative of much higher MuSC
survival, were observed in bioconstructs into which both MuSCs
and MRCs had been introduced (Fig. 2b).
We then tested the myogenic potential of our bioconstructs
in vivo. We again generated bioconstructs containing either
MuSCþ /MRC or MuSCþ /MRCþ populations, or biocon-
structs containing no cells at all (MuSC /MRC formulation;
hydrogel alone). All MuSCs expressed Luciferase. We then
transplanted these bioconstructs into the TA muscles of
immunocompromised (NOD.CB17-Prkdcscid/J or NOD-SCID)
mice with acute VML injuries (Supplementary Fig. 3), and
we measured bioluminescence non-invasively 30 days post
transplantation. We found that MuSCþ /MRCþ bioconstructs
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Figure 1 | Mouse model of VML results in irrecoverable loss of function and structure. (a) VML surgical procedure. From left to right, a photographic
sequence shows tattooing and surgical ablation with a micro-blade (indicated by a yellow arrowhead) of a deﬁned mass from a TA muscle. (b) Model of TA
muscle with ablation injury. A rendition of the rectangular pocket created within the TA by the surgical excision is shown. (c) Representative H&E staining
of whole TA muscle cross-sections. An uninjured TA muscle (left panel) and a TA muscle 30 days following VML injury (right panel) are shown. The tibia
and the extensor digitorum longus (EDL) muscle have been drawn for each image to facilitate the orientation and the anatomy of the TA muscles. A dashed
line indicates the area corresponding to the muscle area removed in the surgical procedure. For the VML model image, the boxed areas are shown in higher
magniﬁcation to the right (scale bar¼ 2mm). Left box: peripheral ﬁbrotic scarring is observed in place of the excised muscle (indicated by arrow bars).
Right box: a ﬁbrotic scar can be seen extending into the belly of the TA muscle (indicated by arrow head) (scale bar¼ 500 mm). (d) Quantiﬁcation
of TA muscle tissue masses. TA muscles were weighed immediately following dissection. For muscles subjected to VML injuries, the ablated muscle
tissues were immediately weighed (white bar) and added to the muscle mass remaining 30 days after the ablation (red bar). Comparisons were made to
unablated muscles. (e) Force production, measured through a force transducer, of TA muscles 30 days after VML injuries compared with uninjured
control TA muscles. Contractions were induced in vivo through direct sciatic nerve stimulation (left graph) or ex vivo by inducing contraction directly
through electrical stimulation in a culture bath (right graph) (n¼ 6). Data are±s.e.m. For statistical analysis, t-tests were used. *Po0.05; **Po0.001;
****Po0.00001.
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emitted bioluminescence signals almost 40 times higher than
those of MuSCþ /MRC bioconstructs (Fig. 2c,d). Together,
these results suggest that MRCs support MuSC viability within
bioconstructs in vitro and in vivo.
ECs are necessary and sufﬁcient to sustain MuSCs. Recreating
and supporting the extended vascular networks required to
sustain growth of new engineered tissue during regenerative
interventions remains a critical challenge25,35. ECs participate
during the regenerative process of injured muscles by providing
trophic support to MuSCs and contributing in the angiogenic
process32,36–38. We thus asked whether ECs might be having
a critically speciﬁc role in sustaining MuSCs in vivo, within
the transplanted bioconstructs. To test this, we generated
bioconstructs with Lucþ MuSCs alone or along with ECs
(unlabelled) and transplanted them into VML injuries. When we
measured bioluminescence 21 days later, we found that ECs
partially rescued the loss of MuSC viability measured when
transplanted into bioconstructs without MRCs (Supplementary
Fig. 4a). In addition, when we transplanted bioconstructs
containing Lucþ MuSCs and either Luc MRCs including ECs
or Luc MRCs depleted of ECs, we found that supplementing
MuSCs with MRC population that did not contain ECs was less
effective than with the population of MRCs containing ECs
(Supplementary Fig. 4a). These results suggest that ECs are
required for the enhancing effect of the total MRC population to
sustain MuSCs viability, expansion and engraftment within
bioconstructs transplanted in VML injuries, and also that ECs
alone are sufﬁcient to produce nearly the full effect of the total
MRC population.
We next asked what the fate of transplanted ECs was during
the process of de novo tissue formation. We generated
bioconstructs containing either Lucþ MuSCs and Luc MRCs
or Luc MuSCs and Lucþ ECs together with the other Luc
MRCs. We then monitored bioluminescence from transplanted
MuSCs or ECs non-invasively. We found that both MuSCs and
ECs survived and expanded within the bioconstructs up to
21 days after the transplantation (Supplementary Fig. 4b,c). These
results indicate that ECs can grow within transplanted biocon-
structs, persisting in the de novo tissue.
Finally, to test whether donor-derived ECs were not only
providing trophic support to MuSCs, but also engrafting and
possibly participating in de novo vasculogenesis, we transplanted
bioconstructs containing DS-Red MuSCs and DS-Redþ ECs
together with the rest of DS-Red MRCs. Surprisingly,
immunohistological analysis of the transplanted TA muscles
30 days later showed extensive distribution of donor-derived ECs
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Figure 2 | MRCs support MuSCs in de novo myoﬁbre formation. (a) Representative FACS plot of MRCs. Lower limb muscles were dissected and digested
to obtain a mononucleated cellular suspension. These cells were marked using cell speciﬁc surface antigens as described in the ‘Results’ and in the
‘Methods’ sections and were analysed using FACS. Five populations were isolated: muscle stem cells (MuSCs), hematopoietic cells (HCs), endothelial cells
(ECs), ﬁbro-adipogenic progenitor cells (FAPs) and ﬁbroblast-like cells (FLCs). The relative percentages of each cell population are 10%, 25%, 39%, 8%
and 18%, respectively (n¼6). (b) Quantiﬁed results of in vitro bioluminescence generated from cultured bioconstructs containing Lucþ MuSCs, either
alone (MuSCþ/MRC ) or in combination with Luc MRCs (MuSCþ/MRCþ ). Bioconstructs were cultured for three days, and bioluminescence was
measured each day (n¼4). (c) Representative images of bioluminescence measured from mice 10 days after transplantation of bioconstructs in left TA
muscles immediately following VML injury (d) Quantiﬁed results of non-invasive imaging of transplanted bioconstructs. Bioconstructs with no cells
(MuSC/MRC ), Lucþ MuSCs (MuSCþ/MRC ), or Lucþ MuSCs in addition to Luc MRCs (MuSCþ/MRCþ ) were transplanted into TA muscles
that had received VML injuries. Bioluminescence was measured 10 days following transplantation (n¼4). Data are±s.e.m. For statistical analysis, t-tests
were used. *Po0.05; **Po0.001.
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in vascular structures around myoﬁbres within transplanted
bioconstructs (Supplementary Fig. 4d). These results suggest that
ECs are a critical MRC population capable of engrafting and
contributing to vasculogenesis within in vivo engineered de novo
muscle tissue.
Perfusion in a bioreactor enhances MuSCs viability. Culturing
cells within 3D substrates results in a loss of cell viability9,39.
During the process of generating bioconstructs with Lucþ
MuSCs, we observed substantial bioluminescent signal decay
in vitro within two hours of reconstitution, continuing up to
24 h (Fig. 3a). Perfusion systems have proven a practical
tool for remedying the loss of cell viability in 3D culture
conditions35,39,40. We thus sought to establish a perfusing
bioreactor to be used immediately after curing of the hydrogel
to test whether this would enhance MuSC viability.
To create perfusing bioreactors, we generated tubular culture
chambers made of Tygon E-3603 biopolymer with an inner
diameter similar to the scaffolds. Inside these chambers,
bioconstructs were fabricated by reconstituting scaffolds using
a micromanipulator to control the coordinates of injection
and a micropump to regulate the ﬂow rate and volume of the
hydrogel-cell suspension being injected. Finally the culture
chambers were connected to a bioreactor allowing perfusion of
the bioconstructs with recirculating media (Fig. 3b). We initially
validated perfusion performance in cell-free bioconstructs by
introducing a blue dye into the recirculating media. We found
that the dye diffused efﬁciently throughout the bioconstructs
(Supplementary Fig. 5a). We then tested the effects of perfusion
of culture medium on the survival of cells within the
bioconstructs by measuring the bioluminescence of bioconstructs
reconstituted with Lucþ MuSCs plus MRCs. Over the next
24 h, the bioluminescent signal in bioconstructs cultured under
static conditions decreased signiﬁcantly relative to initial
measurements. Conversely, when we perfused the bioconstructs
with culture medium, the bioluminescence increased over time
(Fig. 3a).
To test whether these perfused bioconstructs resulted in
improved MuSC engraftment and de novo muscle ﬁbre formation
in vivo, we generated MuSCþ /MRCþ bioconstructs using
MuSCs that had been transduced with a lentivirus expressing
Luciferase and GFP. After culturing these bioconstructs under
either static or perfused conditions for 24 h, we transplanted them
into TA muscles of mice with acute VML injuries. We imaged
bioluminescence of these bioconstructs immediately prior to
transplantation and then again immediately after transplantation
to establish the initial readings (Fig. 3c). We then monitored
and recorded bioluminescent signalling non-invasively over the
next 30 days (Fig. 3d). Whereas the bioluminescent signals
from TA muscles transplanted with static bioconstructs increased
several fold over that time, the signals from muscles transplanted
with the perfused bioconstructs increased by almost three orders
of magnitude (Fig. 3d). After 30 days, muscles transplanted
with perfused bioconstructs emitted bioluminescent signals more
than two orders of magnitude greater than those transplanted
with static bioconstructs.
Consistent with bioluminescence imaging, immunohistochem-
ical analysis of bioconstructs 10 days following transplantation
revealed regions of Luciferaseþ /GFPþ myoﬁbres in muscles
transplanted with the perfused bioconstructs (Supplementary
Fig. 5b); only rare Lucþ /GFPþ myoﬁbres were observed in
muscles transplanted with the static bioconstructs. Histological
analysis conﬁrmed the presence of muscle ﬁbres within the
transplanted perfused bioconstructs (Fig. 3e). Only rarely were
myoﬁbres found within transplanted static bioconstructs. These
results suggest that treatment of VML lesions using MuSCs
incorporated into a scaffold can be enhanced by perfusing the
cell/hydrogel/scaffold bioconstructs to maintain cell viability
prior to transplantation.
Bioconstructs restore active force generation in VML. The
development of a successful stem cell-based strategy for repairing
VML must restore not only muscle structure but also
muscle function. To test whether we could repair the loss of
function measured earlier in our force production experiments
(Fig. 1e,f), we generated MuSCþ /MRCþ , MuSCþ /MRC ,
MuSC /MRCþ and MuSC /MRC bioconstructs to treat
acute VML lesions using all of the optimisations described above
(Fig. 4a). The MuSCs used were isolated from mice expressing the
reporter ﬂuorescence protein ‘enhanced YFP’ (eYFP; isolated
from a Pax7CreER/ROSA26eYFP mouse)41. We then surgically
transplanted these bioconstructs into TA muscles with acute
VML injuries. After 30 days, we measured isometric tetanic forces
of these muscles. First, we measured the force generated in vivo
by connecting the distal TA tendon to a force transducer and
electrically stimulating the sciatic nerve. None of the treatments
showed a signiﬁcant improvement in force production when
compared with untreated VML conditions using this form of
stimulation (Fig. 4b). As an alternative, we measured muscle
forces ex vivo. When directly stimulated in this manner, the
muscles transplanted with MuSCþ /MRCþ bioconstructs
generated active forces that were signiﬁcantly greater than
untreated VML muscles (Fig. 4c), suggesting that the force
measurements by sciatic nerve stimulation were limited by
the innervation of new myoﬁbres as opposed to their intrinsic
force-generating potential. By contrast, MuSCþ /MRC ,
MuSC /MRCþ and MuSC /MRC bioconstructs did not
show any signiﬁcant improvement compared with untreated
VML conditions (Fig. 4c). Furthermore, TA muscle mass was
partially restored in the MuSCþ /MRCþ treatment group and, to
a lesser extent, in the MuSCþ /MRC treatment group (Fig. 4d).
In the MuSC /MRCþ and MuSC /MRC controls, the
increase in mass was essentially that of the transplanted
bioconstructs. These results suggest that MuSCþ /MRCþ
bioconstructs are capable of functionally restoring muscle tissue
by generating de novo myoﬁbres, but may not be functionally
innervated 30 days after treatment.
Bioconstructs restore muscle and vascular structure. To test
whether the observed restoration of biomechanical force
production was associated with structural repair of the VML
injury, we performed histological analysis on the TAs from the
experiments described above following force measurements.
Morphometric analysis of whole TA cross-sections revealed
that, relative to untreated VML-injured muscles, only muscles
treated with MuSCþ /MRCþ bioconstructs showed a statistically
signiﬁcant increase in size as measured by cross-sectional
areas (CSAs) (Fig. 5a,b). Bioconstructs reconstituted with the
MuSCþ /MRCþ populations also exhibited markedly reduced
ﬁbrosis (Fig. 5a,c). From these data, we concluded that the
current bioconstruct reconstitution represents a treatment
strategy that provides a pro-regenerative environment in regions
that are severely impaired by VML injuries.
Our next experiment was designed to further characterize
the contribution of donor-derived cells to the formation of
new muscle ﬁbres. Therefore, we transplanted bioconstructs
containing donor MuSCs expressing eYFP to quantify de novo
eYFPþ myoﬁbres within those regions. We found at 10 days
following transplantation that treatment with MuSCþ /MRCþ
bioconstructs generated donor-derived myoﬁbres adjacent to
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms15613 ARTICLE
NATURE COMMUNICATIONS | 8:15613 | DOI: 10.1038/ncomms15613 |www.nature.com/naturecommunications 5
106
108
3
2
2
9
8
10
2
10
2
Counts
Counts
107
106
105
104
1
BC
BC
UM
UM
7 14 21 28
Days
105
104
103
102
101
100
0 2 8 24
Static
a b
c
d
e
Perfused
Static
Perfused
***
**
*
Hours
Pre Op
priming in culture
Static Perfused
Post Op
implant in vivo
G
FP
LU
C
Pe
rfu
se
d
St
at
ic
Bi
ol
um
in
es
ce
nc
e
(ph
oto
ns
 cm
–
2  
s–
1 )
Bi
ol
um
in
es
ce
nc
e
(ph
oto
ns
 cm
–
2  
s–
1 )
Figure 3 | Perfusion of bioconstructs in a bioreactor improves MuSC efﬁcacy. (a) Perfusion of bioconstructs sustains MuSC viability in vitro.
Bioconstructs were reconstituted with Lucþ MuSCs and Luc MRCs and then cultured for 24 h. Bioluminescence was measured at different time points,
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chamber capable of hosting one bioconstruct (bottom panel). (c) Representative bioluminescence and ﬂuorescence images of bioconstructs before and
after transplantation. Bioconstructs were generated with Lucþ/GFPþ MuSCs and Luc/GFP MRCs, cultured under either perfused or static conditions,
and imaged non-invasively before transplantation (Pre Op, left panels). Bioconstructs that had been imaged previously in vitro were imaged non-invasively
in vivo immediately following transplantation (Post Op, right panels). (d) Quantitative results comparing bioluminescence of perfused and static
bioconstructs at periodic intervals following transplantation into VML injuries (n¼4). (e) (Left panels) Representative H&E-stained cross-sections of
muscles 10 days after receiving perfused or static bioconstruct transplantation to treat VML injuries. Bioconstructs (BC) are shown adjacent to unablated
muscle (UM) (scale bar¼ 500 mm). (Right panels) The regions outlined by the yellow boxes in the left panel are magniﬁed here (scale bar¼ 200mm
Data are±s.e.m. For statistical analysis, t-tests were used. *Po0.05; **Po0.001; ***Po0.0001.
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scaffold (Supplementary Fig. 6a). Analysis of cross-sections and
longitudinal-sections of muscles 30 days following bioconstructs
transplantation revealed donor-derived myoﬁbres homogenously
distributed throughout the injured regions (Fig. 5d,g). The degree
of maturation of these myoﬁbres was reﬂected by sarcomeric
striations (Supplementary Fig. 6b). MuSCþ /MRCþ biocon-
structs yielded greater numbers of eYFPþ myoﬁbres (413±87)
than did the MuSCþ /MRC (92±21) or MuSC /MRC
bioconstructs (no ﬁbres) (Fig. 5e). Furthermore, eYFPþ myo-
ﬁbres in muscles transplanted with MuSCþ /MRCþ biocon-
structs had greater CSAs than did those in muscles transplanted
with MuSCþ /MRC bioconstructs (Fig. 5f). Together, these
results provide further evidence that the generation of new
muscle tissue in VML injuries transplanted with bioconstructs
containing MuSCs is enhanced by the inclusion of MRCs.
Immunohistochemical staining for blood vessels, deﬁned as
CD31þ structures, revealed that the MuSCþ /MRCþ -treated
muscles were more extensively vascularized compared with
muscles treated with MuSCþ /MRC or MuSC /MRC
bioconstructs (Fig. 5h,i). To conﬁrm that the CD31þ structures
were functionally engrafted with the host vasculature, we
injected Isolectin intravenously into the circulation and ﬁxed
the muscles 10min following the injection. Immunohistochem-
istry conﬁrmed the presence of CD31þ /Isolectinþ vessels within
the transplanted regions, surrounding donor-derived ﬁbres
(Supplementary Fig. 7a,b). Our ﬁndings, consistent with our
results on the role of ECs (Supplementary Fig. 4), suggest that
treatments containing MRCs help to overcome the challenge of
vascularisation by supporting de novo functional vasculogenesis
in concert with the de novo muscle formation.
Exercise improves innervation and functional recovery. Next,
we turned our attention to the discrepancy observed between forces
measured using direct muscle stimulation compared with sciatic
nerve stimulation (Fig. 4c versus Fig. 4b). We hypothesized that
this discrepancy might be due to the fact that new muscle tissues
generated by the transplanted bioconstructs had not been efﬁciently
innervated in our acute VML model. To test this hypothesis,
we analysed the neuromuscular junctions (NMJs) associated
with regenerated myoﬁbres within our transplanted bioconstructs
using ﬂuorescently-labelled a-bungarotoxin (aBTX). We found
fewer mature NMJs 30 days after treatment in regions of
the transplanted bioconstructs in both the MuSCþ /MRCþ and
the MuSCþ /MRC treatment groups compared with unablated
regions of the same muscles (Supplementary Fig. 8a,b). These data
provide evidence of incomplete innervation of muscle ﬁbres formed
de novo from MuSCs in transplanted bioconstructs.
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Figure 4 | Treatment of acute VML restores mass and force production. (a) Schematic model of our VML treatment procedure using bioconstructs. TA
muscles are isolated from donor mice (1). These muscles are used to obtain either: decellularized scaffolds, MuSCs, MRCs or ECM proteins to generate
hydrogels (2). Scaffolds are reconstituted with isolated cells and hydrogel to generate bioconstructs (3). Bioconstructs are cultured in a bioreactor while the
hydrogel cured, allowing media to perfuse across the bioconstructs (4). Once ready, bioconstructs are transplanted into VML injured TA muscles (5).
(b) In vivo force production measurements of TA muscles treated with different bioconstructs following VML injury. After 30 days, the distal tendons were
attached to a force transducer and contractions were induced through sciatic nerve stimulation (n¼8). (c) Ex vivo force production measurements. The
same muscles measured in b were then dissected and cultured in a chamber. The distal tendons were attached to a transducer and contractions
were induced electrically in the culture bath (n¼8). (d) The mass of each TA muscle was measured following ex vivo force measurements (n¼ 6).
In (b–d) average values of muscles that did not received VML injuries are labelled ‘uninjured’ and are indicated by a blue dotted line; average values of
muscles that received a VML injury without any treatment are labelled ‘VML’ and are indicated by a red dotted line. Data are±s.e.m. For statistical analysis,
t-tests were used. **Po0.001; ****Po0.00001, n.s.: not signiﬁcant.
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Figure 5 | Treatment of VML improves and restores tissue structure. (a) Representative immunoﬂuorescence (IF) images of cross-sections of
VML-injured TA muscles treated with different bioconstructs. Three of the same muscles used for force productions in Fig. 4 were sectioned and
immunostained (scale bar¼ 1mm). (b) Measurements of whole muscle tissue areas for all muscles assessed in Fig. 5 (n¼6). (c) Measurements of ﬁbrotic
tissue areas within total muscle areas quantiﬁed in b (n¼6). (d) Representative IF cross-sectional images showing donor-derived eYFPþ myoﬁbres
following treatment. Muscles treated with bioconstructs generated using eYFPþ MuSCs and eYFP MRCs were harvested after taking force
measurements. The panel shows a region in which a bioconstruct was implanted within a VML-injured TA muscle. The yellow arrow indicates peripheral
ﬁbrotic scarring as illustrated in Fig. 1. The white arrow indicates residual scaffold surrounded by de novo myoﬁbres (scale bar¼ 500mm). (e) Quantiﬁcation
of the number of eYFPþ myoﬁbres in muscles treated with bioconstructs generated with either eYFPþ MuSCs alone or together with eYFP MRCs
(n¼6). (f) Quantiﬁcation of cross-sectional areas of the myoﬁbres counted in e (n¼ 6). (g) Representative IF longitudinal images showing donor-derived
eYFPþ myoﬁbres in transplanted bioconstructs (scale bar¼ 500mm). The left panel shows a low magniﬁcation image of a TA muscle centred on the
transplanted bioconstruct region (scale bar¼ 500mm). The yellow arrow indicates the peripheral ﬁbrotic scarring adjacent to the unablated muscle (UM),
which is overlying de novo muscle ﬁbres within the bioconstruct (BC). The orange arrows indicate two stiches securing the BC within the tissue. The white
arrow indicates a region of residual scaffold. The right panel shows at higher magniﬁcation image of donor-derived eYFPþ myoﬁbres. The white arrows
again indicate regions of residual scaffold (scale bar¼ 50mm). (h) Representative IF images showing blood vessels structures formed by endothelial cells
(CD31þ ) within regions of transplanted bioconstructs (scale bar¼ 100 mm). (i) Quantiﬁcation of blood vessels from regions of transplanted bioconstructs
in muscles with VML injuries (n¼6). Data are±s.e.m. For statistical analysis, t-tests were used. **Po0.001; ***Po0.0001.
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Re-innervation of muscle ﬁbres in injured tissue and in
transplanted muscle explants can take 430 days to occur4. For
this reason, we chose to test for force production improvements
at a later time point, 60 days after the treatment. Similar to 30-day
time points, the results observed 60 days after treatment revealed
that the bioconstruct show improved ex vivo but not in vivo force
performances (Supplementary Fig. 9a). Consistently with ex vivo
forces, immunohistochemistry analysis conﬁrmed extensive
regions of donor-derived myoﬁbres in the transplanted regions
(Supplementary Fig. 9b). These results demonstrate that de novo
engineered muscle tissue persists in the host and restores forces
ex vivo for up to at least 2 months. The fact that in vivo forces
were still not restored even 2 months after the treatment indicates
the need for additional therapeutic interventions to improve
innervation.
Exercise has been proposed to improve muscle function
following VML injuries42,43. Based on these suggestions, we
hypothesized that a regime of exercise could further enhance the
process of de novo myogenesis and innervation following the
treatment of VML injuries with bioconstructs. First, we analysed
the capacity of mice that received VML injuries to recover
performances in voluntary running. Using computer-assisted
wheels, we measured the time required for injured mice to return
to the daily running habits measured for uninjured control mice.
We found that following VML injury, it took 7 days to return
to running these control distances (Supplementary Fig. 10a).
Next, we tested the effect of running on mice that received
VML injuries. We exercised these mice for seven days on a
treadmill either immediately after the injury or after seven days of
rest. We found that early exercise delayed muscle regeneration
(smaller myoﬁbre CSAs) and increased ﬁbrosis (higher content of
Collagen deposition), whereas later exercise instead accelerated
myogenesis and reduced ﬁbrotic formation (Supplementary
Fig. 10b,c) Based on these results, we chose to begin exercise
after 1 week of rest for mice with VML injuries. We imposed an
exercise regimen on VML-injured mice that had received either
no treatment or treatment with bioconstructs generated with
eYFPþ MuSCs and eYFP MRCs. We exercised mice for
3 weeks on a treadmill for 60min daily, and we compared then
with non-exercised control groups.
To test the functional deﬁcits resulting from VML injuries,
we performed gait analysis 30 days following the treatment of
non-exercised or exercised mice. Using a scale in which untreated
mice exhibited maximum deﬁcit and uninjured mice showed
no deﬁcit, we found that treating VML with bioconstructs in
non-exercised mice resulted in a functional recovery toB75% of
that of uninjured mice (Fig. 6a,b). However, treatment with
exercise resulted in a further improved score to B95% of the
valued from uninjured mice (Fig. 6a,b). Next, we measured
forces in vivo trough neural stimulation. Following exercise,
muscles from exercised mice showed improved force production
compared with muscles from non-exercised mice, showing a
partial rescue of forces measured in vivo after VML injuries
(Fig. 6c). Similarly, ex vivo force measurements also showed
greater improvement in exercised mice (Fig. 6d). Moreover,
despite similar muscle masses, treated muscles with VML injuries
from mice that received exercise outperformed muscles from
non-exercised mice in terms of force generation by either in vivo
or ex vivo stimulation (Supplementary Fig. 11a). Taken together,
these results show that exercise is capable of restoring forces
in vivo of treated muscles with VML injuries.
We hypothesized that exercise was improving forces in vivo by
ameliorating the deﬁcit of innervation observed in non-exercised
mice with VML injuries treated with bioconstructs. To test this,
we performed immunohistochemistry on the same muscles
analysed for force production. We ﬁrst measured the number
of NMJs associated with donor-derived myoﬁbres within treated
VML-injured TA muscles, from the proximal to the distal regions
(Fig. 6e). Our results show that exercise increased the number of
NMJs associated with donor-derived myoﬁbres (eYFPþ ) across
the muscle compared with muscles of non-exercised mice
(Fig. 6f). Next, we measured the number of mature NMJs. These
were characterized by the typical ‘pretzel-like’ morphology and
positive immunostaining for Synaptophysin and Neuroﬁlament,
proteins expressed in the synaptic vesicles and the axons of
the nerve, respectively (Fig. 6g). Again, exercise resulted in
improved maturation of NMJs within transplanted muscles of
exercised mice compared with muscles from non-exercised mice
(Fig. 6h). The distribution of NMJs correlated with the in vivo
forces in individual muscles. Muscles from non-exercised mice
clustered in the lower end of the range, whereas muscles
from exercised mice clustered in the upper end, indicating
a shift toward larger masses and stronger in vivo forces with
exercise (Supplementary Fig. 11b).
In addition, we asked whether exercise had any positive effect
on vasculogenesis. Within transplanted bioconstructs regions, we
quantiﬁed the average number of blood vessels per donor-derived
myoﬁbre and we found that exercise increased their number by
twofold in regions with de novo myoﬁbres (Supplementary
Fig. 12a). Finally, we quantiﬁed the level of ﬁbrosis and we
found that exercise signiﬁcantly reduced ﬁbrosis compared with
non-exercised mice (Supplementary Fig. 12b,c). Taken together,
these results show that exercise improves the treatment of VML
by reducing ﬁbrosis and enhancing vascularisation.
Bioconstructs partially repair chronic VML injuries. Chronic
lesions represent the more common clinical presentations
of VML injuries and are characterized by extensive muscle
tissue remodelling and scar formation1–3,44. To test if our
MuSCþ /MRCþ bioconstructs treatment strategy was also
capable of partially restoring muscle structure and function in
chronic lesions, we induced VML lesions and waited 30 days
before transplanting MuSCþ /MRCþ bioconstructs. We then
waited another 30 days and assessed the biomechanical and
histological outcomes. Assessment of muscle force generation
in vivo showed, as with the acute treatments, no signiﬁcant
increase compared with controls (scar tissue debridement but no
bioconstruct treatment) (Supplementary Fig. 13). However,
ex vivo stimulation of treated muscles showed a partial recovery
of force production when compared with controls
(Supplementary Fig. 13), suggesting that even chronic VML
lesions may be amenable to treatment using our MuSC
bioconstructs approach.
Immunohistochemical analyses showed local areas of donor-
derived myoﬁbres with few NMJs (Supplementary Fig. 15).
Morphometric analysis revealed no signiﬁcant difference in de
novo myoﬁbre CSA compared with ﬁbres generated in VML
injuries treated acutely (Supplementary Fig. 15a). However,
despite myoﬁbre CSAs that were similar to the acute model
(Supplementary Fig. 15a), there were signiﬁcantly fewer eYFPþ
myoﬁbres in the chronic model (Supplementary Fig. 15b),
consistent with smaller force improvements after treatments
(Supplementary Fig. 13). These results show that bioconstructs
generated with MuSCs and MRCs can be employed to treat
chronic VML injuries, partially restoring structure and function.
Bioconstructs made of human MuSCs and MRCs. Designing
treatments for VML injuries in mice is an important step to
treating similar injuries in humans. With this translational goal in
mind, we wanted to test whether transplantation of human
MuSCþ /MRCþ bioconstructs would be as effective as murine
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MuSCþ /MRCþ bioconstructs. We thus used FACS to isolate
human MuSCs and MRCs from operative samples obtained from
consenting patients. We then generated human MuSCþ /MRCþ
and MuSCþ /MRC (which we designate as hMuSCþ /hMRCþ
and hMuSCþ /hMRC , respectively) bioconstructs according to
the procedures identical to those done with mouse cells. We
transplanted these bioconstructs into immunodeﬁcient NOD/scid
IL2Rgnull (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ or NSG) mice
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with acute VML injuries. After 30 days, we assessed human
myoﬁbre formation within the muscles. Histochemical analysis
showed that treatment with the hMuSCþ /hMRCþ bioconstructs
resulted in muscle tissue formation and minimal ﬁbrotic
inﬁltration (Fig. 7a). By contrast, transplanted MuSCþ /MRC
bioconstructs resulted in negligible de novo muscle formation
(Fig. 7a). Instead, the transplanted area appeared to consist pri-
marily of residual scaffold, appearing as a ﬁbrotic scar.
Immunohistochemical analysis revealed that hMuSCþ /hMRCþ -
treated muscles contained myoﬁbres within the regions of the
transplanted bioconstructs that stained positively for human Integrin
a7b1 (Fig. 7b). Quantiﬁcation of muscles transplanted with
hMuSCþ /hMRC bioconstructs revealed rare Integrin a7b1þ
myoﬁbres within the region of the transplant (Fig. 7c). Conversely,
muscles treated with hMuSCþ /hMRCþ bioconstructs resulted in
numbers of donor-derived myoﬁbres comparable to those observed
following treatment with murine cells (Fig. 7c; compared
with Fig. 5f). Moreover, immunostaining of human Lamin-A, a
perinuclear protein, revealed positive nuclei across the regions of the
transplanted hMuSCþ /hMRCþ bioconstructs (Fig. 7b). Only a
limited number of Lamin-Aþ human nuclei were visible in muscles
treated with the hMuSCþ /hMRC bioconstructs. We then tested
force production of muscles treated with hMuSCþ /hMRCþ
bioconstructs after 30 days and found that, as with bioconstructs
containing murine cells, in vivo forces did not improve signiﬁcantly
but ex vivo forces did (Fig. 7d,e). Together, these results demonstrate
that hMuSCs can contribute to myoﬁbre generation in and
functional restoration of VML injuries, suggesting the possibility of
using these bioconstructs in a scalable approach to treat VML
injuries in humans.
Discussion
VML is an injury of the skeletal muscle caused by major trauma,
such as battle wounds or tumour excision1,2. Endogenous MuSCs,
despite their remarkable regenerative capacity, are unable to
restore the muscle structure and function compromised by VML
injuries12,40. Current treatments are limited to scar tissue
debridement and autologous tissue transfer at the site of tissue
defect4,6. By combining decellularized muscle tissue scaffolds with
freshly isolated MuSCs and MRCs, we were able to generate
bioconstructs that, when transplanted in irrecoverable acute VML
injuries in a murine model, resulted in de novo myoﬁbre
formation in vivo. Moreover, transplanted bioconstructs were
able to partially restore structure and ex vivo force production,
but insufﬁcient innervation of the de novo myoﬁbres. However,
when treatment was followed by physical therapy, innervation
was improved and in vivo forces were restored. Similarly, chronic
VML injuries, a challenging clinical condition complicated by
severe ﬁbrosis and tissue remodelling, responded positively to our
treatment. We were also able to repair and restore muscle
structure and function by the transplantation of bioconstructs
established with human MuSCs and MRCs, highlighting the
translational potential of this approach. These results, a product
of our combined bioengineering and stem cell technologies,
have important implications in the development of future stem
cell-based therapies for the treatment of VML injuries.
The use of ECM-based biomaterials to treat VML injury has
yielded variable results45,46. To date, these treatments have shown
some degree of myoﬁbre regeneration with limited improved
force production in animal models19. It has been suggested that
the application of ECM proteins and factors derived from
decellularized tissues might act as biochemical stimuli, capable of
inducing tissue regeneration15, but this remains to be
demonstrated. When structure and function are too severely
compromised, as is the case in most VML injuries, ECM-based
materials alone cannot effectively rescue the tissue but can result
instead in signiﬁcant ﬁbrotic formation that limits efﬁcacy of
these treatments18,47.
An alternative strategy that combines myogenic cells with
scaffolds has been shown to improve the efﬁcacy of scaffolds
alone. Engrafting cultured myogenic cells in decellularized
scaffolds prior to transplantation in animal models results in
de novo muscle ﬁbre formation that persists in the host following
transplantation into VML injuries contributing, at least partially,
to muscle structure and force production16,23,48. However,
cultured cells show limited efﬁcacy, compared with freshly
isolated stem cells, in their ability to regenerate tissues9,49.
Recently, VML treatments utilising minced muscle preparations,
including all of the MRCs, have yielded promising results,
including partial structural and functional recovery28,50. Our
results showed that treating VML with bioconstructs containing
only MuSCs had a limited capacity to restore tissue structure and
function. Conversely, when we transplanted bioconstructs
generated with MuSCs and MRCs, we observed remarkably
improved force production and partial regeneration of structure.
Among the multiple MRC populations, we investigated the
particular role of ECs and found that they are necessary and
sufﬁcient to sustain MuSC expansion and engraftment within
transplanted bioconstructs. These ECs were able to engraft
and participate in de novo vasculogenesis within transplanted
bioconstructs. Other MRCs may also have critical roles. Within the
HCs, different CD45þ populations can be stimulated by implanted
biomaterials within traumatic injuries51. It was recently shown that
decellularized ECM scaffolds implanted in muscles with VML
injuries can modulate the immune microenvironment through a
mTOR/Rictor-dependent T helper 2 pathway that guides
interleukin-4-dependent macrophage polarisation, an important
process for functional muscle recovery51.
Figure 6 | Exercise improves innervation of de novo myoﬁbres and improves forces in vivo. (a) Representative image of a mouse during a gait analysis
(top) and the gait footprints collected during the analysis (bottom). Mice were positioned in a transparent treadmill and a camera was positioned
underneath to record the gait. (b) Quantiﬁcation of the gait ‘disability score’ resulting from the analysis of 47 parameters (see Methods) (n¼6). (c) In vivo
force production measurements of TA muscles treated with bioconstructs following VML injury in non-exercised or exercised mice. After 30 days, the
distal tendons were attached to a force transducer and contractions were induced through sciatic nerve stimulation (n¼ 6). (d) Ex vivo force production
measurements from non-exercised or exercised mice. The same muscles measured in c were then dissected and cultured in a chamber. The distal tendons
were attached to a transducer and contractions were induced electrically in the culture bath (n¼6). (e) (Left) Representative IF image of transplanted
bioconstruct. Yellow arrows indicate donor-derived (eYFPþ) myoﬁbres with NMJs (aBTXþ ) within regions of the transplanted bioconstruct. (Right)
Higher magniﬁcation of an NMJ associated with a donor-derived myoﬁbre (scale bars¼ 50 mm). (f) Quantiﬁcation of NMJs in whole cross-sections of
transplanted bioconstructs along 3mm lengths of TA muscles. Muscles were either uninjured and exercised (‘-VML, þ Ex’) or subjected to VML injury and
bioconstruct treatment (‘þVML, þTx’) without (‘-Ex’) or with (‘þ Ex’) exercise (n¼ 5). (g) (Larger panels) Representative IF images of myoﬁbres with
mature NMJs (aBTXþ and also stained positive for Synaptophysin (SynPh) and Neuroﬁlament (NFL)) within regions of transplanted bioconstructs
(scale bar¼ 100 mm). (Smaller panels) Higher magniﬁcation of a mature NMJ (scale bar¼ 10 mm). (h) Quantiﬁcation of mature NMJs in whole
cross-sections of uninjured muscles or of injured muscles with transplanted bioconstructs along 3mm lengths of TA muscles characterized as in f (n¼4).
Data are±s.e.m. For statistical analysis, t-tests were used. **Po0.001; ****Po0.00001.
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Our results show an average of 4400 myoﬁbres generated
de novo per transplanted bioconstruct (for example, Fig. 6e).
A single murine myoﬁbre of a lower limb muscles generates an
average of 0.5mN absolute force52. Our ex vivo results, which
showed an average of 250mN force rescue per leg (Fig. 5c), are
consistent with these data. These improvements in force
production were contrasted by persisting anatomical deﬁcits.
Although a clear improvement over untreated VML injuries, our
treatment showed lingering signs of ﬁbrosis and irregular
myoﬁbre morphology. Continued optimisations of our
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Figure 7 | Human MuSCs and MRCs generate de novo human muscle tissue in VML injuries. (a) Representative histological images of murine TA
muscles following VML injury and treatment with hMuSC/hMRC bioconstructs. The yellow dashed lines indicate the regions where bioconstructs were
transplanted (scale bar¼ 2mm). (b) Representative IF staining of mouse and human proteins in the same muscles as in a (scale bar¼ 50mm).
(c) Quantiﬁcation of the number of human Integrin a7b1þ myoﬁbres in muscles treated with bioconstructs generated with either human MuSCs alone or
together with human MRCs (n¼4). (d) Bioconstructs were generated with: no cells, freshly isolated mouse MuSCs and MRCs, or freshly isolated human
MuSCs and MRCs. These bioconstructs were transplanted in VML injuries of TA muscles of immunocompromised mice. Muscles were analysed for force
production 30 days later. The graph shows quantiﬁcation of in vivo force production comparing the three conditions. (e) The same muscles analysed
in d were analysed and quantiﬁed for ex vivo force production. Data are±s.e.m. For statistical analysis, t-tests were used. **Po0.001.
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bioconstruct formulation and transplantation processes, for
example, using more reﬁned MRC-based treatments, might
further improve tissue reconstruction following VML.
Our measurements of force production in vivo did not show
nearly the improvements in force generation as those observed
when muscles were stimulated ex vivo (for example, Fig. 5b versus
Fig. 5c). We hypothesized that this discrepancy might be
explained by inefﬁcient innervation of the de novo muscle
engineered within the transplanted bioconstructs. Immunohisto-
chemical assessment within the regions of the transplanted
bioconstructs showed that only a limited number of myoﬁbres
stained positive for mature NMJs 30 days following treatment
(Supplementary Fig. 8a,b). As it can take 42 months for
damaged muscle to fully re-innervate53, it is reasonable to expect
improved innervation at later times points. However, when we
examined muscles 60 days following treatment, in vivo force
production did not outperform untreated muscles. It might be
possible to further improve innervation by supporting the
bioconstruct treatments with exercise42,43. There is evidence
that aggressive exercise immediately after surgical implantation of
ECM scaffolds to VML injuries has signiﬁcant beneﬁt on matrix
remodelling14,54. Moreover, positive effects of exercise have been
observed within 30 days following muscle grafting in rats,
resulting in improved re-innervation53–55. In agreement with
these reports, when we followed treatment of VML injuries with
bioconstructs and exercise, we found enhanced maturation of
innervation and enhanced force production in vivo at 30 days
following treatment. Moreover, we showed that exercise increases
vascularisation and reduces ﬁbrosis of de novo tissues engineered
in VML injuries. This evidence indicates that exercise
enhances the regenerative potential of VML treatments by
helping to overcome limitations in current methods, such as
limited innervation and excessive ﬁbrosis. Alternative strategies
might include delivering neurogenic factors within the
bioconstructs56.
Moving forward, the availability of MuSCs will need to be
addressed to regenerate large muscle volumes. As noted above,
expanding MuSCs in vitro results in a loss of stem cell potency,
ultimately limiting their value for therapeutic use9,49,57. Recently,
however, new strategies to preserve cultured MuSC function and
potency have been proposed49,58. These strategies are based on
recreating the physiological MuSC microenvironment, or niche, to
mimic the biochemical, molecular and/or biophysical conditions
through which potency is maintained26,49,59. The most common
approaches, which include addition of factors or small molecules to
the growth media and recreation of the physiological substrate
stiffness on which cells are cultured, have demonstrated that it is
possible to preserve, at least partially, the original ‘stemness’ of
mouse and human MuSCs, renewing their candidacy for use in
transplantation after prolonged periods in culture26,49,59,60. Similar
strategies could be adopted to expand freshly isolated MRCs.
Our ﬁndings represent an important step forward in validating
the therapeutic potential of stem cell-based treatments in
engineering tissues capable of treating VML injuries and, more
generally, in muscle reconstruction. Although there is certainly a
need for a substantial scaling aimed for treatment of VML injuries
of large muscles, other important translational applications
include the reconstruction of congenitally defective or injured
small human muscles, such as cleft lip muscles or eye muscles.
These aspects represent clinical conditions that could readily
beneﬁt from treatment strategies such as those described here.
We demonstrate the translational potential of this reconstructive
tissue engineering strategy by replicating our results using human
MuSCs and MRCs, offering the exciting possibility that these
therapeutic strategies might be readily translated to a clinical
setting.
Methods
Animals. C57BL/6, ROSA26eYFP and FVB-Tg(CAG-luc,-GFP)L2G85Chco/J male
mice were obtained from Jackson Laboratory. NOD/MrkBomTac-Prkdcscid female
mice were obtained from Taconic Biosciences. Pax7CreER mouse were provided by
Dr Charles Keller, Oregon Health and Science University, Portland, OR, USA61.
Tamoxifen injections for Cre recombinase activation were performed
administering ﬁve doses (5mg per mouse) every 2 days and waiting a minimum of
7 days before using the animals experimentally61. To control for tamoxifen
injection toxicity, we injected all mice with tamoxifen. Mice were housed and
maintained in the Veterinary Medical Unit at the Veterans Affairs Palo Alto Health
Care Systems. Animal protocols were approved by the Administrative Panel on
Laboratory Animal Care of Stanford University.
Human skeletal muscle specimens. Subjects ranged in age from 51 to 75 years.
The human muscle biopsy specimens were taken after patients gave informed
consent, as part of a human studies research protocol which was approved by the
Stanford University Institutional Review Board. All experiments were performed
using fresh muscle specimens, according to availability of the clinical procedures.
Sample processing for cell analysis began within one hour of specimen isolation. In
all studies, standard deviation reﬂects variability in data derived from studies using
true biological replicates (that is, unique donors). Data were not correlated with
donor identity.
Ablation model. NOD/SCID or NSG mice of ages 3 months (chronic study) or
4 months (acute study) were placed under 2.5% isoﬂurane anaesthesia for surgical
procedures. An incision was made directly over the TA muscle and was extended
proximally up to the patellar tendon and distally to the myotendinous junction of
the TA muscle. The thin layer of fascia covering the TA muscle was dissected away
and a 2 7mm stencil was placed on the muscle. A scalpel was used to make a
2mm deep cut around the stencil removing a 2 7 2mm piece of the muscle and
creating B40% ablation of the TA muscle. The excised muscle was weighed to
conﬁrm the weight to be 15±1.5mg. If no immediate transplant was to be
performed, the incision was sutured closed and Buprenorphine (0.1mg kg 1) and
Baytril (5mg kg 1) were administered.
MRC Isolation and puriﬁcation. Muscles were harvested from hind limbs
and mechanically dissociated to yield a fragmented muscle suspension using a
gentleMACS dissociator (Miltenyl Biotec). This was followed by a 90min digestion
in a Collagenase II-Ham’s F10 solution (500 units per ml; Invitrogen). After
washing, a second digestion was performed for 30min with Collagenase II
(100 units per ml) and Dispase (2 units per ml; Invitrogen). The resulting cell
suspension was washed, ﬁltered and stained with VCAM-biotin (clone 429;
BD Bioscience), CD31-APC (clone MEC 13.3; BD Bioscience), CD45-APC
(clone 30-F11; BD Bioscience) and Sca-1-Paciﬁc-Blue (clone D7; Biolegend)
antibodies at a dilution of 1:75. Streptavidin-PE-cy7 was used to amplify the
VCAM signal (BD Biosciences, 1:75) and FACS grade DAPI dilactate for
non-viable cell exclusion (D3571 Invitrogen). For Pax7CreER/ROSA26eYFP mice,
MuSCs were directly sorted by endogenous eYFP protein expression. Human
MuSCs were puriﬁed from fresh operative samples60–62. Operative samples were
carefully dissected from adipose and ﬁbrotic tissue and a disassociated muscle
suspension prepared as described for mouse tissue. The resulting cell suspension
was then washed, ﬁltered and stained with anti-CD31-Alexa Fluor 488 (clone
WM59; BioLegend; #303110, 1:75), anti-CD45-Alexa Fluor 488 (clone HI30;
Invitrogen; #MHCD4520, 1:75), anti-CD34-FITC (clone 581; BioLegend; #343503,
1:75), anti-CD29-APC (clone TS2/16; BioLegend; #303008, 1:75) and anti-NCAM-
Biotin (clone HCD56; BioLegend; #318319, 1:75). Unbound primary antibodies
were then washed and the cells incubated for 15min at 4 C in streptavidin-PE/Cy7
(BioLegend) to detect NCAM-biotin. Cell sorting was performed on calibrated
BD-FACS Aria II or BD FACSAria III ﬂow cytometers equipped with 488-nm,
633-nm and 405-nm lasers to obtain the MuSC population. A small fraction of
sorted cells was plated and stained for Pax7 and MyoD to assess the purity of the
sorted population. For the FACS gating strategy, see Supplementary Information.
Decellularized scaffold preparation. ECM-based scaffolds for use as biocon-
structs were generated form decellularized muscle tissue as follows. Lower limbs of
C57BL/6 mice were dissected such that both the proximal and distal ends of the TA
muscles remained in mechanical tension by their natural attachment points. The
lower limbs were then placed in a decellularization buffer (1% sodium dodecyl
sulfate, Sigma B01587, in phosphate-buffered saline (PBS) solution) and allowed to
react for 3 days, then rinsed in fresh PBS every 24 h for 5 days. The resulting
decellularized TAs were then dissected from the bone and transferred into the
tubular culture chambers of the bioreactor (made of Tygon E-3603 biopolymer),
where they were held in place with stainless steel minutien pins (FST, 0.2 diameter,
10mm length, AM00030).
Bioconstruct preparation. Scaffold preparation began with loading our isolated
cells and ECM-based hydrogels into insulin syringes. These syringes were then
positioned on a SP220I syringe pump (World Precision Instruments; Sarasota,
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms15613 ARTICLE
NATURE COMMUNICATIONS | 8:15613 | DOI: 10.1038/ncomms15613 |www.nature.com/naturecommunications 13
FL, USA) to allow precise control over the ﬂow rate of the injections. Freshly
puriﬁed cells were mixed in ECM-based hydrogel solution at the ratios of: 150,000
MuSCs; 100,000 HCs; 140,000 ECs; 40,000 FAPs; 70,000 ﬁbroblast-like cells. Evans
Blue dye was added to the cell solution allowing visualization of the injected
regions. A total volume of 15ml was loaded into insulin syringes with fresh
reconstitution solution, and mounted on a syringe pump. The decellularized
scaffold, pinned inside the tubular culture chambers, was mounted on a
micromanipulator and positioned in front of the syringe needle. The needle was
then carefully driven through the decellularized scaffold, and 20 ml of the cell per
hydrogel solution was deposited at a ﬂow rate 1.5 ml min 1. To ensure that cells
were distributed evenly throughout the entire scaffold, the needle was retracted
from the scaffold at a rate of 500mm every 30 s. The resulting bioconstructs, still
contained within the tubular culture chamber, were then transferred into an
incubator set at 37 C/5% CO2. Each culture chamber was connected to a
bioreactor to allow perfusion with fresh media while the hydrogel cured.
Bioreactor design. The bioreactor was designed to sustain the 3D cell culture
within each bioconstruct by perfusing it with fresh culture media. The bioreactor
was made of four tubing holders, connected by luer-lock adapters to 14 inch Tygon
E-3603 biopolymer tubular culture chamber that were epoxied to pulley wheels and
connected to swivel tubing adaptors. The swivel tubing adaptors let ﬂuid ﬂow freely
through the system, while allowing internal rotation. The tubing employed for the
circulation of media was made of gas permeable silicon tubing (Masterﬂex
BioPharm Plus platinum-cured silicone pump tubing, L/S 16, 25 ft) organized
in a serpentine pattern to allow optimal media oxygenation and gas exchange.
Circulation of media was controlled by an automatic pump (Geniethouch, Lucca
Technologies), at a ﬂow rate of 1mlmin 1. Bioconstructs were positioned in the
bioreactor culture tubular chambers before starting the reconstitution with
hydrogels and cells. The chambers were then immediately connected to the tubing
of the bioreactors after reconstitution, and the recirculation was started 30min
after the curing of the hydrogel and initiating the gelation process. Each biocon-
struct remained in the bioreactor for not longer than 2 h before being transplanted.
Bioconstruct transplantation. For the acute VML model, bioconstructs were
transplanted immediately after the ablation surgery was performed (n¼ 6). The
bioconstructs were inserted directly into the injury site and were sutured into place
at both the proximal and distal ends using 10–0 sutures (Vivryl V966G, Ethicon).
The intact host muscle tissue was then folded over the top of the transplant and
sutured in place to optimize coverage of the scaffold. The skin incision was then
sutured closed and Buprenorphine (0.1mg kg 1) and Baytril (5mg kg 1) were
administered. For the chronic VML model (n¼ 6), an incision was made over
the scar and a debridement surgery was performed to remove the scar tissue.
Transplantation of the bioconstructs was then performed similar to acute injuries.
Sham controls received incision and debridement but not bioconstruct
transplantation.
Voluntary running. Each subject was singly housed in cage with computer-
controlled running wheels. All animals had access ad libitum to food, water and
wheel running. Prior to the experimental period, subjects were given 3 days to
acclimate to the cages and their surroundings. At day 3, the experimental group
(n¼ 4) had internal ablations performed on both legs as described in ‘Ablation
Model’ section in ‘Methods’. Mice were then returned to their cages with
computer-controlled running wheels and allowed to run freely. Non-exercised
controls were singly housed in cages with locked wheels. Cycles of 12-h day per
night light were used in the rooms housing the mice and their cage bedding was
changed once a week. Each cage wheel was attached to a counter motor that was
then attached to data acquisition software that recorded the number of rotations
that occurred during each 15min interval for 2 weeks.
Treadmill running. Before each mouse began its exercise programme, it was
acclimated to the Exer 3/6 treadmill (Columbus Instruments) for 3 days with a
10min running period at 10mmin 1 each day (n¼ 6). At the start of each
training regimen, the mice slowly acclimated to the speed of the treadmill by
beginning at 7mmin 1 and increasing the speed at 0.5mmin 1 until a speed of
12mmin 1 was reached. The mice then ran progressively longer each day for
7 days at a speed of 15mmin 1 for 3 weeks. A low voltage was applied to a grate
at the end of the treadmill to encourage the mice to continue running for the
duration of the protocol.
Gait analysis. Gait capture and analysis was performed using a Digigait System
(Mouse Speciﬁcs). Before videos were recorded, mice were allowed to acclimate in
the run chamber for 5min and then ran at 10 cm s 1 for another 5min to
acclimate to belt movement. Once the mouse was determined to be comfortable,
the brightness, contrast and viewing frame were adjusted so that the paws could be
easily seen within the captured images. The belt speed was then increased to
20 cm s 1 and recording of the gait was immediately begun. Videos were recorded
for as long as it took to obtain at least three segments of 3 s of uninterrupted
running (running in which the mouse did not stop, jump or put its paws on the
walls of the chamber). Run videos were captured on a ﬂat surface and at a 10 degree
incline. Once the segments were obtained, they were post-processed and analysed
by the software provided with the Digigait imaging system. Each segment was
individually adjusted with a binary threshold adjustment tool to remove any noise
and to establish well deﬁned paw areas. Data were manually adjusted to remove
any artifacts in the paw area-plots the system included in the results. Once the data
had been checked for accuracy, they were inserted into a MATLAB programme to
sort through the parameters, perform statistical comparisons and return an overall
gait score.
In vivo force production. Mice were placed under 2.5% isoﬂurane anaesthesia to
perform the TA isolation surgery. A 2-inch incision was made from the iliac
crest distally along the thigh to begin the process of exposing the sciatic nerve.
A landmark fat pad was then cut, allowing separation of the cranial thigh muscles
and access to the sciatic nerve. The fascia surrounding the nerve was dissected away
and a small piece of Paraﬁlm was placed under the nerve for later placement of the
stimulatory nerve cuff. Another incision was made from the patellar tendon down
to the myotendinous sheath located in the ankle to ensure complete TA muscle
exposure. Saline was added throughout the procedure to ensure the tissue remained
hydrated. Using a surgical microscope, the myotendinous sheath was cut to free the
distal tendon of the TA for manipulation. The TA muscle was then carefully
separated from the surrounding muscles using a blunt dissection technique. The
medial fascia between the TA muscle and the tibia was carefully cut away up until
the point where ﬁbres began inserting into the bone (where the tibia begins to
bow inward). On the lateral side, the fascia between the TA muscle and the
other lower-limb muscles was dissected away and any additional muscle groups
separated to ensure they did not contribute to force production. The distal end of
the TA tendon was superglued between two ﬂat bars, providing a leverage point
past which a knot could not slip during contraction events. The TA tendon was
then cut distal to the bars to free up the muscle for subsequent force production.
An Aurora Scientiﬁc 1300-A Whole Mouse Test System was used to gather force
production data. The mouse was placed on the stage and a pin was placed through
an L bracket behind the patellar tendon to secure the knee joint and ensure
isometric muscle contractions. The ankle of the mouse was also secured using
tape to ensure the leg remained in the same position throughout the testing
procedure. At one end a knot was tied around the distal tendon, secured by
the afﬁxed toothpicks, and at the other it was afﬁxed to the muscle lever. The
lever was positioned such that it was perpendicular to the TA muscle. A small,
two wire, bipolar nerve cuff was then positioned around the sciatic nerve in
such a way that both electrodes were touching the nerve. The previously placed
Paraﬁlm strip helped to ensure that unwanted stimulation of the surrounding
tissue did not occur.
Data acquisition. Calibrated Dynamic Muscle Control and Analysis Software
(Aurora Scientiﬁc) and a 701C Stimulator (Aurora Scientiﬁc) were used to acquire
muscle force measurements. First, the rough optimal voltage was found by using
course voltage adjustments and a manual stimulation on the 701C stimulator to
determine what voltage yielded the most powerful twitches. Then, Force–Length
measurements were obtained by stretching the TA muscle and measuring the
twitch forces produced at 0.5mm increments using six electrical pulses of 1ms
each at 1Hz. When performing twitch tests a 1-minute rest period was allowed
between each electrical pulse. Once the optimal length (stretched length at which
the highest twitch force was observed) was determined, a more rigorous voltage
recruitment analysis was performed by measuring the twitch force produced at
1 volt intervals from 1 to 10 volts using the same twitch protocol as above. If the
twitch force was found to still be rising at 10 volts, testing was performed until the
values plateaued. Having determined the optimal length and voltage, a 500ms
tetanic stimulation at 100Hz was performed to ensure the knot and force output
remained stable during tetanic stimulation. Once validated, a tetanic stimulation
frequency sweep from 60 to 140Hz at 20Hz intervals was performed to determine
the maximum tetanic force produced by the muscle. A rest period of 2min was
given between each tetanic stimulation. Imaging was performed in blinded fashion:
the investigators performing the imaging did not know the identity of the
experimental conditions for the transplanted cells.
Ex vivo force production. An 800A in vitro apparatus (Aurora Scientiﬁc) was used
to perform the ex vivo testing of the TA muscles. The testing chamber, along with
the Krebs solution (Sigma), was kept at 25 C using an external water heater. To
help ensure tissue viability, a 95% O2, 5% CO2 mixture was used to oxygenate the
testing chamber along with a petri dish containing Krebs solution. Mice were killed
and the lower limbs excised from the ankle to B0.5 inches above the patellar
tendon to ensure the entire TA muscle was removed. The legs were then pinned
down in the petri dish coated with an elastomer (Sylgard-184, Dow Corning). The
TA muscles were carefully dissected from the legs under a microscope and held
under tension until attached to the force transducer lever. The muscle was attached
to the force transducer lever by directly tying a knot around the top of the patellar
tendon. The TA muscle was then attached to the force transducer lever and the
bottom of the testing apparatus to secure the TA muscle in place. The testing
chamber was raised around it to immerse the muscle in Krebs solution. A similar
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testing procedure to the in vivo protocol was used ex vivo except no voltage
recruitment testing was performed. Imaging was performed in blind: the
investigators performing the imaging did not know the identity of the experimental
conditions for the transplanted cells.
Bioluminescence imaging. Bioluminescent imaging was performed using the
Xenogen IVIS-Spectrum System (Caliper Life Sciences). Mice were anaesthetized
using 2% isoﬂurane at a ﬂow rate of 2.5 lmin 1 (n¼ 4). Intraperitoneal injection
of D-Luciferin (50mgml 1, Biosynth International Inc.) dissolved in sterile PBS
was administered. Immediately following the injection, mice were imaged for 30 s
at maximum sensitivity (f-stop 1) at the highest resolution (small binning). Every
minute a 30 s exposure was taken, until the peak intensity of the bioluminescent
signal began to diminish. Each image was saved for subsequent analysis. Imaging
was performed in blinded fashion: the investigators performing the imaging did not
know the identity of the experimental conditions for the transplanted cells.
Bioluminescence image analysis. Analysis of each image was performed using
Living Image Software, version 4.0 (Caliper Life Sciences). A manually-generated
circle was placed on top of the region of interest and resized to completely
surround the limb or the speciﬁed region on the recipient mouse. Similarly,
a background region of interest was placed on a region of a mouse outside the
transplanted leg.
Functional vascularisation assessment. Mice received a tail vein injection of
200mm of biotinylated-Isolectin diluted in saline solution at a concentration of
2mgml 1 (n¼ 3). Tail veins were dilated prior injection by heat using a lamp
while mice were awake. Each injection was performed using a sterile 24-gauge
needle and a sterile 1ml syringe. Following the injections, mice were single caged
for 10min before being killed to collect the muscles for analysis.
Tissue harvesting. TA muscles were carefully dissected away from the bone,
weighed and placed into a 0.5% PFA solution for ﬁxation overnight. The muscles
were then moved to a 20% sucrose solution for 3 h or until muscles reached their
saturation point and began to sink. The tissues were then embedded and frozen in
optimal cutting temperature medium and stored at  80 C until sectioning.
Sectioning was performed on a Leica CM3050S cryostat that was set to generate
10mm sections. Sections were mounted on Fisherbrand Colorfrost slides. These
slides were stored at  20 C until immunohistochemistry could be performed.
Histology. TA muscles were ﬁxed for 5 h using 0.5% electron-microscopy-grade
paraformaldehyde and subsequently transferred to 20% sucrose overnight. Muscles
were then frozen in optimal cutting temperature, cryosectioned at a thickness of
10mm and stained. For colorimetric staining with Hematoxylin and Eosin (Sigma)
or Gomorri Trichrome (Richard-Allan Scientiﬁc) samples were processed
according to the manufacturer’s recommended protocols.
Immunostaining. A 1 h blocking step with 20% donkey serum/0.3% Triton in PBS
was used to prevent unwanted primary antibody binding for all samples. Primary
antibodies were applied and allowed to incubate over night at 4 C in 20% donkey
serum/0.3% Triton in PBS. After four washes with 0.3% PBST, ﬂuorescently
conjugated secondary antibodies were added and incubated at room temperature
for 1 h in 0.3% PBST. After three additional rinses each slide was mounted using
Fluoview mounting media.
Antibodies. The following antibodies were used in this study. The source of each
antibody is indicated. Mouse: eMHC (DSHB, #F1.652, 1:50); CD31 (BD Pharmingen,
#553371, 1:100); GFP (Invitrogen, #A11122, 1:250); Luciferase (Sigma-Aldrich,
#L0159, 1:200); Collagen I (Cedarlane Labs, #CL50151AP, 1:200); HSP47
(Abcam, #ab77609, 1:200); a-Bungarotoxin (Life Technologies, # B-1196, 1:500);
Laminin (Millipore, #MAB1903, 1:750); Synaptophysin (Abcam, #ab32594, 1:300);
Neuroﬁlament (Life Technologies, #MA5-14981, 1:200). Human: Lamin-A
(Abcam, #ab108595, 1:200); Integrin (AbD Serotec, # MCA699PE, 1:200).
Secondary antibodies (AlexaFluor, Invitrogen,1:1,000). Biotinylated GSL I-IsolectinB4
(Vector Laboratories, #B-1205).
Hydrogels. All hydrogels were generated according to the manufacturer. Each
muscle-derived ECM-based hydrogel was generated as follows: skeletal muscle
tissue was decellularized with a 1% sodium dodecyl sulfate solution, made by
adding appropriate volumes of 20 PBS, 10 sodium dodecyl sulfate, and
ultrapure water. Rinses and solution changes were repeated every 24 h until the
tissue was completely white (usually 3–4 days). Isopropyl alcohol was used to
remove the presence of lipids after decellularization to prevent inhibition during
subsequent gelation of the digested material. Frozen ECM was lyophilized and
milled (Wiley Mini-Mill, #40 or #60 ﬁlter) to generate a particulate for subsequent
protease digestion. In order to liquefy the ECM, milled ECM was partially digested
in pepsin. After 48 h, the liquid ECM was titrated to pH 7.4, 1 PBS and a ﬁnal
material concentration of 6mg ECM per ml 1. Material was then aliquoted, frozen
and lyophilized for long-term storage for up to 1 year at  80 C. When ready for
use, lyophilized ECM was resuspended in an equivalent volume of sterile water for
use. Details are presented in Table 1.
Imaging. Samples were imaged using standard ﬂuorescent microscopy and either a
 10 or  20 air objective. Volocity imaging software was used to adjust excitation
and emission ﬁlters and came with pre-programmed AlexaFluor ﬁlter settings,
which were used whenever possible. All exposure times were optimized during the
ﬁrst round of imaging and then kept constant through all subsequent imaging.
Image analysis. Image J was used to calculate the percentage of area composed of
Collagen by using the colour threshold plugin to create a mask of only the area
positive for Collagen. That area was then divided over the total area of the sample
which was found using the free draw tool. All other analyses were performed using
Volocity software and manually counting ﬁbres using the free draw tool and also
counting the number of nuclei, eMHCþ ﬁbres, NMJs and blood vessels by hand.
Lentiviral transduction. Luciferase and GFP protein reporters were subcloned
into a third generation HIV-1 lentiviral vector (CD51X DPS, SystemBio). To
transduce freshly isolated MuSCs cells were plated at a density of 200,000 cells per
well on a six-well plate and were incubated with 60 ml of concentrated virus and
8 ml polybrene. Plates were spun for 5min at 3,200 g, and for 1 h at 2,500 g at 25 C.
Cells were then washed with fresh media two times, scraped from plates, spun
down and resuspended in the ﬁnal volume according to the experimental
conditions.
Statistical analysis. Unless otherwise noted, all statistical analyses were
performed using GraphPad Prism 5 (GraphPad Software). For statistical analysis,
t-tests were used. All error bars represent s.e.m.; *Po0.05; **Po0.001;
***Po0.0001.
Data availability. The data that support the ﬁndings of this study are available
from the corresponding author upon reasonable request.
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